Abstract
Background:
Grover’s disease has been associated with a number of medications including sulfadoxine-pyrimethamine, recombinant interleukin (IL)-4, ipilimumab, and BRAF inhibitors. To our knowledge, Grover’s disease has not been reported in association with interleukin-17 inhibitors.
Case Description:
A 47-year-old female with plaque psoriasis developed Grover’s disease 3 months following initiation of brodalumab. Discontinuation of brodalumab and initiation of certolizumab pegol and methotrexate led to resolution of her rash.
Conclusion:
This case highlights Grover’s disease as a potential adverse effect of brodalumab therapy. In patients who develop Grover’s disease with brodalumab, modification of therapy may be considered due to the bothersome nature of the rash.
Get full access to this article
View all access options for this article.